Welcome to our dedicated page for 908 Devices news (Ticker: MASS), a resource for investors and traders seeking the latest updates and insights on 908 Devices stock.
908 Devices Inc. develops purpose-built handheld chemical analysis devices for point-of-need use in health, safety and defense technology applications. Its news centers on Mass Spec and FTIR product activity, installed-device growth, recurring revenue, and applications such as narcotics identification, toxic exposure screening and security-threat analysis.
Company updates also cover acquisitions and portfolio expansion, including the completed purchase of NIRLAB AG and its AI-powered, cloud-connected near-infrared spectroscopy platform for narcotics screening. Other recurring items include quarterly financial results, revenue outlooks, executive and strategy appointments, funded partnership revenue, and investor conference participation.
908 Devices (Nasdaq:MASS) granted inducement stock options to four new non-executive employees under its 2026 Inducement Plan, effective June 1, 2026. The awards cover an aggregate 179,912 shares with an exercise price of $8.63, matching the June 1, 2026 closing price.
Options vest over four years: 25% after one year, then 36 equal monthly installments for the remaining 75%, subject to continued service, and were approved under Nasdaq Listing Rule 5635(c)(4).
908 Devices (Nasdaq: MASS) announced that CEO Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 16th Annual East Coast IDEAS Investor Conference on June 10, 2026, at 8:35 a.m. ET.
The presentation will be webcast via the conference website and the 908 Devices investor relations page.
908 Devices (Nasdaq: MASS) reported Q1 2026 revenue of $13.4 million, up 14% year-over-year, with recurring revenue of $4.0 million (30% of total). Adjusted gross margin rose to 57% (290 bps improvement). Installed base grew 23% to 3,903 devices. Cash was $111.7 million with no debt. The company acquired NIRLAB AG after quarter end and raised 2026 revenue guidance to $67.0M–$70.0M (19%–25% growth).
908 Devices (Nasdaq: MASS) has completed the acquisition of NIRLAB AG, a Lausanne-based developer of AI-powered, cloud-connected near-infrared (NIR) spectroscopy for handheld narcotics screening. The deal includes $15 million upfront consideration ($13M cash, $2M stock) and up to $8 million in additional 908 Devices common stock tied to milestones over 20 months.
NIRLAB’s handheld analyzes >400 drugs, quantifies purity and THC/CBD, and is proven with over 1,000,000 field analyses; the company employs 15 people and was founded in 2021 as a University of Lausanne spin-out. A conference call/webcast on Q1 2026 results is scheduled May 6, 2026 at 8:30 AM ET.
908 Devices (Nasdaq: MASS) will report first quarter 2026 financial results before market open on Wednesday, May 6, 2026.
Management will host a live webcast and conference call beginning at 8:30 a.m. Eastern Time; live audio is available in the Investors section at www.908devices.com and will be archived for replay within 24 hours.
908 Devices (Nasdaq: MASS) appointed Kola Otitoju as Chief Business & Strategy Officer and granted inducement equity on April 21, 2026. The company awarded 110,193 RSUs and options to buy 146,789 shares at an exercise price of $7.26.
The RSUs vest equally May 1, 2027, May 1, 2028, and May 1, 2029; the option vests 1/3 on May 1, 2027 and the remainder in 24 monthly installments thereafter. Awards were made under the 2026 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
908 Devices (NASDAQ:MASS) will present at the Sidoti Small Cap Conference on Wednesday, March 18, 2026. CEO Kevin J. Knopp and CFO Joe Griffith will deliver a virtual presentation starting at 1:45 p.m. ET and will host investor meetings.
A live audio webcast with slides is available via the conference link, and an archived webcast will be posted in the company’s Investors section at www.908devices.com.
908 Devices (Nasdaq: MASS) reported Q4 2025 revenue of $17.4M (+21% YoY) and full-year 2025 revenue of $56.2M (+18% YoY). Recurring revenue was $19.5M (35% of 2025). Q4 delivered GAAP gross margin 53% and positive Adjusted EBITDA $0.7M. Cash and marketable securities were $113.0M with no debt. The company provided 2026 revenue guidance of $64.5M–$67.5M (15%–20% growth).
Management cites margin improvements, installed base growth to 3,736 devices, and continuing operational focus following the March 2025 divestiture.
908 Devices (Nasdaq:MASS) will participate in two investor conferences in March with scheduled fireside chats: TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4 at 9:10 a.m. ET and Leerink Global Healthcare Conference on Monday, March 9 at 1:40 p.m. ET.
According to the company, live and archived webcasts will be available in the Investors section of its website at www.908devices.com.
908 Devices (Nasdaq: MASS) will report fourth quarter and full year 2025 financial results before market open on March 3, 2026. Management will host a conference call and webcast at 8:30 a.m. ET, with live audio on the company Investors website and archived replay within 24 hours.